June 1, 2018 (Vol. 38, No. 11)
The Breath Biopsy® product range allows academic, clinical, and pharmaceutical researchers to quickly discover and validate breath-based biomarkers in early detection and precision medicine research activities. The Breath Biopsy platform is a new diagnostic modality capable of detecting biomarkers of disease, and also exogenous compounds such as volatile drug metabolites. The ReCIVA Breath Sampler and new Breath Biopsy Kits ensure consistent and reliable collection of breath samples. VOC (volatile organic compound) biomarkers present in breath can be analyzed with high sensitivity and selectivity in Owlstone Medical’s Breath Biopsy Services Laboratory or a researcher’s own laboratory. Availability of Breath Biopsy kits makes breath biopsy widely accessible to clinical researchers and pharma companies including those without the in-house analytical capability for breath samples, without requiring these companies to purchase high-cost capital equipment.